Patents Assigned to Merck
  • Lyophilisates having improved reconstitutability
    Patent number: 6770678
    Abstract: The present invention relates to lyophilisates having an improved dissolution rate which can be reconstituted in a particle-free manner, which is achieved by re-warming the solutions already drawn off to from 30° to 95° C. directly in the freeze drier.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: August 3, 2004
    Assignee: Merck Patent GmbH
    Inventors: Thelka Kurz, Ludwig Krueger, Brigitte Hesse, Arnd Karnatz
  • Transparent medium having angle-selective transmission or reflection properties and/or absorption properties
    Patent number: 6767633
    Abstract: The invention relates to a transparent medium comprising multilayer pigments having angle-selective reflection or transmission properties and/or absorption properties, and to their use, in particular in transparent thermal insulation systems (TTIs).
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: July 27, 2004
    Assignee: Merck Patent GmbH
    Inventors: Elke Steudel, Hans-Dieter Brückner, Gerhard Pfaff, Peter Reynders, Christoph Schmidt, Carsten Brabänder, Wolfgang Hechler
  • Substituted piperidines as melanocortin receptor agonists
    Patent number: 6767915
    Abstract: Certain novel 4-substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: July 27, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Raman K. Bakshi, Khaled J. Barakat, Yingjie Lai, Ravi P. Nargund, Brenda L. Palucki, Min K. Park, Iyassu K. Sebhat, Zhixiong Ye, Arthur A. Patchett
  • Substituted imidazoles having cytokine inhibitory activity
    Patent number: 6767908
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which may be useful for the treatment of cytokine mediated diseases such as arthritis.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: July 27, 2004
    Assignee: Merck & Co., Inc
    Inventors: Christopher F. Claiborne, Nigel J. Liverton, David A. Claremon
  • Enantioselective bioreduction for the preparation of integrin receptor antagonist intermediates
    Patent number: 6764842
    Abstract: The present invention relates to a novel enantioselective bioreduction using a yeast microorganism for the preparation of the chiral allylic alcohols of structural formula I (R is hydrogen or methyl) which are useful in the asymmetric synthesis of integrin &agr;v&bgr;3 receptor antagonists.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: July 20, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Michael G. Sturr, Russell Fieldon Boyd, Kodzo Gbewonyo, Joseph Nti-Gyabaah, David J. Pollard, James Christopher McWilliams, Kathleen A. Telari
  • Apatite-coated metallic material, process for its preparation, and its use
    Patent number: 6764769
    Abstract: The invention relates to a novel apatite-coated metallic material having improved surface quality and biocompatibility, a process for its preparation, and the use of the material for bone implants, in particular dental implants, artificial joints and fixative material for accident surgery (osteosynthesis material). The coating in this case consists of a thick covering of hydroxyapatite crystals and/or amorphous calcium phosphate spheres having a specific surface area of less than 15 m2/g.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: July 20, 2004
    Assignee: Biomet Merck GmbH
    Inventors: Bernd Kotte, Jürgen Hofinger, Tanja Hebold
  • Liquid-crystalline medium
    Patent number: 6764722
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds of negative dielectric anisotropy which comprises at least one compound of the formula I1 and at least one compound of the formula I2 in which R11, R12, R21 and Z are as defined in claim 1, and the use thereof for an active matrix display based on the ECB or IPS effect.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: July 20, 2004
    Assignee: Merck Patent Gesellschaft MIT
    Inventors: Melanie Klasen, Clarissa Weller, Kazuaki Tarumi, Matthias Bremer
  • Liquid-crystalline medium
    Patent number: 6764723
    Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy, which contains at least one compound of formula I wherein R1 and R2 are independently of each other an alkyl, alkoxy or alkenyl group with 1 to 12 C atoms, it also being possible for one or more CH2 groups in these radicals to be replaced, in each case independently of one another, by —O—, —CH═CH—, —CO—, —OCO— or —COO— in such a manner that oxygen atoms are not linked directly to one another, Z is OCH2 or CH2O, and m is 0 or 1.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: July 20, 2004
    Assignee: Merck Patent GmbH
    Inventors: Seung-Eun Lee, Nobuo Kubo, Masahiro Iijima, Hideo Ichinose, Yukiomi Tanaka, Shinji Nakajima, Yasushi Sugiyama, Takanori Takeda
  • Dihydropyrimidines and uses thereof
    Publication number: 20040138242
    Abstract: This invention is directed to dihydropyrimidines which are selective antagonists for human &agr;1a receptors. This invention is also related to uses of these compounds for relaxing lower urinary tract tissue, treating benign prostatic hyperplasia and for the treatment of any disease where the antagonism of the &agr;1a receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 6, 2003
    Publication date: July 15, 2004
    Applicants: Merck and Co., Inc., Synaptic Pharmaceutical Corporation
    Inventors: Donghui Cui, Margaret R. Davis, Michael Dunn, Ben E. Evans, Hanumath P. Kari, Bharat Lagu, Dhanapalan Nagarathnam, Kamlesh P. Vyas, Kanyin Zhang
  • DNA vaccine formulations
    Publication number: 20040138165
    Abstract: This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.
    Type: Application
    Filed: October 30, 2003
    Publication date: July 15, 2004
    Applicant: Merck & Co., Inc.
    Inventors: David B. Volkin, Robert K. Evans, Mark Bruner
  • Liquid crystalline medium and liquid crystal display
    Patent number: 6761939
    Abstract: Liquid crystalline media comprising a dielectrically positive component, component A, containing dielectrically positive compounds, comprising one or more compounds of formula I and one or more compounds of formula II and one or more dielectrically neutral compounds of formula IVb wherein the parameters have the meaning defined therein; and wherein two of the 6-membered rings in formula IVb may optionally be linked by an group selected from —CH2—CH2—, —CF2—CF2—, —CF2—O—, —O—CF2— and —CO—O— are sutiable for use in liquid crystal displays, especially active matrix displays.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: July 13, 2004
    Assignee: Merck Patent GmbH
    Inventors: Atsutaka Manabe, Elena Kress, Volker Reiffenrath
  • Method for producing 5-(1-piperazinyl)-benzofuran-2-carboxamide by transition metal-catalyzed amination
    Patent number: 6762300
    Abstract: Process for the preparation of 5-(1-piperazinyl)benzofuran-2-carboxamide in which, as intermediate step, 5-bromosalicylaldehyde or one of its derivatives is reacted in a transition metal-catalysed amination with R2-piperazine, in which R2 is as defined in claim 1.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: July 13, 2004
    Assignee: Merck Patent GmbH
    Inventors: Andreas Bathe, Steffen Emmert, Bernd Helfert, Henning Boettcher
  • Electro-optical liquid-crystal display and liquid-crystal medium
    Patent number: 6761938
    Abstract: A liquid-crystalline medium of positive dielectric anisotropy suitable for use in an electro-optical liquid-crystal display having a realignment layer, for realigning the liquid crystals, whose field has a component parallel to the liquid-crystal layer which is crucial for the realignment, comprises at least one mesogenic compound and at least one compound of the formula I in which the substituents are as defined herein.
    Type: Grant
    Filed: April 18, 2001
    Date of Patent: July 13, 2004
    Assignee: Merck Patent GmbH
    Inventors: Michael Heckmeier, Marcus Reuter, Volker Reiffenrath
  • DNA molecules encoding human NHL a DNA helicase
    Patent number: 6762042
    Abstract: The present invention disclosed isolated nucleic acid molecules (polynucleotides) which encode NHL, a putative DNA helicase. The present invention in turn relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding NHL, substantially purified forms of associated NHL, associated mutant proteins, and methods associated with identifying compounds which modulate NHL, which will be useful in the treatment of various neoplastic disorders. Both a genomic clone containing regulatory and intron sequences, as well as the exon structure and open reading frame of human NHL are disclosed.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: July 13, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Xiaomei Liu, Chang Bai, Michael L. Metzker
  • Mono-, oligo- and poly(3-alkynylthiophenes) and their use as charge transport materials
    Publication number: 20040127592
    Abstract: The invention relates to new conjugated mono-, oligo- and poly(3-alkynylthiophenes). The invention further relates to methods for their preparation, their use as semiconductors or charge transport materials in optical, electrooptical or electronic devices including field effect transistors, electroluminescent, photovoltaic and sensor devices. The invention further relates to field effect transistors and semiconducting components comprising the new mono-, oligo- and polymers.
    Type: Application
    Filed: September 15, 2003
    Publication date: July 1, 2004
    Applicant: Merck Patent GmbH
    Inventors: Martin Heeney, Steven Tierney, Clare Bailey, Iain McCulloch
  • Peroxynitrite rearrangement catalysts
    Publication number: 20040127479
    Abstract: The invention relates to the use of paramagnetic 3-, 8-substituted porphyrin derivatives with various substituents in 13- and 17-positions of the porphyrin skeleton as peroxynitrite rearrangement catalysts.
    Type: Application
    Filed: August 27, 2003
    Publication date: July 1, 2004
    Applicant: Merck Patent GmbH
    Inventors: Gisbert Depke, Margrit Hillmann, Guenter Michl, Johannes Platzek, Detlev Suelzle, Roland Neuhaus
  • Piperidine alcohols
    Patent number: 6756370
    Abstract: The invention relates to compounds of formula (I), wherein R1, R2 and A have the meanings given in claim 1, are potent 5-HT2A antagonists and are suitable for treating psychoses, schizophrenia, depression, neurological disorders, impaired memory, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia and anorexia nervosa, Pre-Menstrual Syndrome and/or for positively influencing obsessive-compulsive disorders, (OCD).
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: June 29, 2004
    Assignee: Merck Patent GmbH
    Inventors: Helmut Prücher, Henning Böttcher, Karl-August Ackermann, Rudolf Gottschlich, Christoph van Amsterdam, Christoph Seyfried, Jürgen Harting, Gerd Bartoszyk, Hartmut Greiner
  • Vapor-deposition material for the production of high-refractive-index optical layers, and process for the production of the vapor-deposition material
    Patent number: 6756137
    Abstract: A vapor-deposition material for the production of high-refractive-index optical layers of titanium oxide, titanium and lanthanum oxide under reduced pressure comprising a sintered mixture having the composition TiOx+z*La2O3, where x=1.5 to 1.8 and z=10 to 65% by weight, based on the total weight of the mixture. The constituents of the mixture are in the range of 10 to 65% by weight of lanthanum oxide, 38 to 74% by weight of titanium oxide and 2 to 7% by weight of titanium.
    Type: Grant
    Filed: December 28, 2001
    Date of Patent: June 29, 2004
    Assignee: Merck Patent GmbH
    Inventors: Uwe Anthes, Martin Friz
  • Gamma-secretase inhibitors
    Patent number: 6756511
    Abstract: Gamma-secretase inhibitors, useful in the treatment or prevention of Alzheimer's disease, are disclosed. The preferred compounds have, as the central portion of the molecule, the structure (a) and are di-astereoisomers of known protease inhibitors.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: June 29, 2004
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Jose Luis Castro Pineiro, Timothy Harrison, Peter Alan Hunt, Alan John Nadin
  • Inhaler
    Patent number: D493220
    Type: Grant
    Filed: May 5, 2003
    Date of Patent: July 20, 2004
    Assignee: Merck Patent GmbH
    Inventors: Simon Burge, Dominic Charles Reber, Roger William Clarke, Michael Edgar Newton, Peter Alan Evans